Celcuity (CELC)

• Market cap: $5.4B
• 1 day: 2.33%
• 5 days: 10.23%
• 1 month: 14.89%
• 3 months: 50.52%
• 6 months: 217.12%
• Year to date: 16.03%
• 1 year: 927.93%
• 5 years: 796.08%
• 10 years: 716.45%
• Sector: Healthcare
• Industry: Biotechnology

About: Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Employees: 87